Given the therapeutic relevance of targeting BCMA in MM, several groups have generated dual CAR targeting BCMA and other antigens of interest, such as MICA/MICB or GPRC5D, to address the efficacy limitations of CAR-T (31–33). The gene discussed is GPRC5D; the disease is Miyoshi myopathy.